|
|
Review a modeling approach employing ANNs using experimental factors combined with simulation-derived parameters plus viscosity data from 27 highly concentrated (180 mg/ mL) mAbs. These ANNs can be used to predict if mAbs exhibit problematic viscosity at distinct concentrations or to model viscosity-concentration-curves. |
|
|
|
Traditional injection force models often lack the accuracy needed for modern, high-viscosity formulations. Understand, through technical details and case studies, how accurate rheological data and syringe characterization enable better predictive models for injection force and ensure confident formulation for autoinjector success. |
|
|
|
In its continued dedication to being a leading outsourcing partner, Lonza collaborated with experts across the industry to detail a comprehensive science- and risk-based approach to CCI for parenteral combination products, which is now built into Lonza practices throughout its development and manufacturing network. |
|
|
|
|
Gain insights into new, large-scale drug product manufacturing expansions supporting vials, prefilled syringes, and highly potent antibody-drug conjugates. See how integrated development and supply services accelerate complex biologic therapies. |
|
|
